Lymphoma & Myeloma 2015 took place October 22-24 in New York, New York.

Breast cancer drug may also work in MCL, myeloma

Bone marrow aspirate
showing multiple myeloma

Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors may be an effective strategy to treat lymphoma and myeloma, according to a presentation at Lymphoma & Myeloma 2015. Palbociclib, an inhibitor of CDK4 and CDK6, received accelerated approval from the US Food and Drug Administration to treat advanced breast... [Read Article]

Post-ibrutinib management in MCL unclear, speaker says

Mantle cell lymphoma

Despite an “unprecedented” single-agent response rate and progression-free survival (PFS) in previously treated mantle cell lymphoma (MCL) patients, those with multiple risk factors have a dismal outcome following ibrutinib failure. So after ibrutinib, what’s next in MCL? That was the question asked at Lymphoma & Myeloma 2015. Peter Martin, MD, of Weill... [Read Article]

Reprogramming the immune system

Electron micrograph
showing Hodgkin lymphoma

Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others, and depletion of malignant cells—may be the best strategy to optimize immune function in B-cell lymphomas, according to Stephen M. Ansell, MD, PhD, of the Mayo Clinic in Rochester, Minnesota.“[A]ll told, there are multiple... [Read Article]

Median DOR, PFS not yet reached for ibrutinib in CLL

Ibrutinib (Imbruvica) capsules
Photo courtesy of
Janssen Biotech, Inc.

Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor produces rapid and durable responses in patients with chronic lymphocytic leukemia (CLL), according to an update presented at Lymphoma & Myeloma 2015. At up to 44... [Read Article]

The search continues for additional targets in CLL

Peripheral blood smear
showing CLL
Image by Mary Ann Thompson

Despite enormous advances in therapies for chronic lymphocytic leukemia (CLL) that target the B-cell receptor (BCR) signaling pathway, there is still room for improvement, according to investigators at the Mayo Clinic. Bruton’s tyrosine kinase (BTK) and phosphoinositide-3 kinase delta (PI3Kδ) inhibitors are major... [Read Article]

Ibrutinib may prove useful in MM, research shows

Bone marrow aspirate
showing multiple myeloma

Results of an open-label, phase 2, dose-escalation study of ibrutinib combined with low-dose dexamethasone suggest the Bruton’s tyrosine kinase (BTK) inhibitor may be useful in treating relapsed or relapsed and refractory patients with multiple myeloma (MM). In the highest dose cohort, 23% of patients experienced a clinical benefit,... [Read Article]